Identification of Potential Biomarkers for Low-Grade Gliomas by Analyzing the Genomics Profiles and CpG Island Methylator Phenotype of Patients in the TCGA Database

Author(s): Bendahou Mohammed Amine, Ibrahimi Azeddine, Boutarbouch Mahjouba

Abstract

Low-grade gliomas are the most common primary brain tumors which affects the central nervous system (CNS), they causes considerable morbidity and represents a therapeutic challenge due to the heterogeneity of their clinical behavior. The objective of this study is to reclassify patients in TCGA databases according to the new 2016 WHO classification by identifying their genomics profiles, glioma CpG island methylator phenotype and studying their survival according to the status of the IDH1 gene. Data were obtained for low-grade gliomas patients from The Cancer Genome Atlas (TCGA), a total of 516 samples were analyzed by TCGA Biolinks R Bioconductor. Patients with astrocytomas had shorter overall survival than those with oligodendrogliomas, they are characterized by mutations in ATRX and TP53 and hypermethylation at the MYT1L and ELAVL4 genes, whereas patients with oligodendrogliomas have mutations in CIC and FUBP1 and hypermethylation at PLCG1 and STAB1 genes. The identification of these biomarkers will improve the diagnosis of low grade gliomas by completing the anatomical pathology tests.